Actinium-225 (Ac-225), 136Ac89, is an important radioisotope in nuclear medicine with applications in the targeted alpha therapy (TAT) in oncology. Ac-225 contains 89 protons and 136 Neutrons, corresponding to atomic mass
Alzheimer’s disease is a complex brain disorder that affects memory, thinking, and behavior, leading to disability and loss of independence. Currently, nearly 10% of Americans 65 or older, an estimated
This blog discusses radiohybrids, theranostics and theranostic pairs. Radiohybrids is a modality in nuclear medicine that allows diagnostic imaging or therapeutic treatment with the same molecular entity depending on the radioelement in the molecule.
The “FIND” Act, or Facilitating Innovative Nuclear Diagnostics Act, aims to improve access to advanced radiodiagnostic imaging for early diagnosis of heart disease, neurological disorders, and cancer to enhance patient
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
Radiotracers are essential tools in nuclear medicine, used for diagnosing and monitoring a variety of diseases, including cancer, brain and heart conditions. However, their production is highly specialized, time-sensitive, and
Radiopharmaceuticals, which combine radioactive isotopes with biomarker identifying molecules, are at the forefront of precision diagnostics and targeted therapy in nuclear medicine. The manufacture of radiopharmaceuticals is a complex process
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The landscape of nuclear medicine and molecular imaging is undergoing significant transformation due to recent changes in reimbursement policies by the Centers for Medicare & Medicaid Services (CMS). These changes
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
Actinium-225 (Ac-225), 136Ac89, is an important radioisotope in nuclear medicine with applications in the targeted alpha therapy (TAT) in oncology. Ac-225 contains 89 protons and 136 Neutrons, corresponding to atomic mass
Alzheimer’s disease is a complex brain disorder that affects memory, thinking, and behavior, leading to disability and loss of independence. Currently, nearly 10% of Americans 65 or older, an estimated
This blog discusses radiohybrids, theranostics and theranostic pairs. Radiohybrids is a modality in nuclear medicine that allows diagnostic imaging or therapeutic treatment with the same molecular entity depending on the radioelement in the molecule.
The “FIND” Act, or Facilitating Innovative Nuclear Diagnostics Act, aims to improve access to advanced radiodiagnostic imaging for early diagnosis of heart disease, neurological disorders, and cancer to enhance patient
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
Radiotracers are essential tools in nuclear medicine, used for diagnosing and monitoring a variety of diseases, including cancer, brain and heart conditions. However, their production is highly specialized, time-sensitive, and
Radiopharmaceuticals, which combine radioactive isotopes with biomarker identifying molecules, are at the forefront of precision diagnostics and targeted therapy in nuclear medicine. The manufacture of radiopharmaceuticals is a complex process
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The landscape of nuclear medicine and molecular imaging is undergoing significant transformation due to recent changes in reimbursement policies by the Centers for Medicare & Medicaid Services (CMS). These changes
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the eReport.
